

KING PHARMACEUTICALS INC

Form 8-K

March 11, 2003

Table of Contents

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 11, 2003

King Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Tennessee
(State or other jurisdiction
of incorporation)

0 24425
(Commission
File Number)

54-1684963
(IRS Employer
Identification Number)

501 Fifth Street, Bristol, Tennessee
(Address of principal executive offices)

37620
(Zip Code)

Registrant's telephone number, including area code: **423-989-8000**

Not Applicable
(Former name or former address, if changed since last report)

TABLE OF CONTENTS

SIGNATURE

Exhibit Index

Press Release

Table of Contents

Item 5. Other Events

King Pharmaceuticals, Inc., a Tennessee corporation, reported today the receipt of a letter from the U.S. Securities and Exchange Commission (SEC) stating that the SEC is conducting an investigation of the company. The letter is accompanied by a subpoena requesting the production of certain documents. King is not aware of the underlying reason for the SEC 's investigation. The requested documents seem to focus on the years 1999 and 2000, and include all documents related to sales of King 's products to VitaRx and Prison Health Services during 1999 and 2000, King 's best price lists, all documents related to the pricing of King 's pharmaceutical products to any governmental Medicaid agency during 1999, the accrual and payment of rebates on Altace® (ramipril) from 2000 to the present, and other general requests. On March 11, 2003, King issued a press release regarding the announcement.

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits

(a) Financial Statements on Businesses Acquired.

None.

(b) Pro Forma Financial Information.

None.

(c) Exhibits.

The following exhibits are filed pursuant to Item 601 of Regulation S-K:

Exhibits:

Exhibit Number	Description of Exhibit
99.1	Press Release of King Pharmaceuticals, Inc. dated March 11, 2003.

Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 11, 2003

KING PHARMACEUTICALS, INC.

By: /s/ James R. Lattanzi
James R. Lattanzi
Chief Financial Officer

Table of Contents

Exhibit Index

Exhibit Number	Description of Exhibit
99.1	Press Release of King Pharmaceuticals, Inc. dated March 11, 2003.